Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry
Abstract Background Treatment persistence is an important consideration when selecting a therapy for chronic conditions such as rheumatoid arthritis (RA). We assessed the long-term persistence of abatacept or a tumor necrosis factor inhibitor (TNFi) following (1) inadequate response to a conventiona...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-06-01
|
Series: | Arthritis Research & Therapy |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13075-019-1917-8 |
id |
doaj-e39399247f704d24b4943cdaec2f0e0f |
---|---|
record_format |
Article |
spelling |
doaj-e39399247f704d24b4943cdaec2f0e0f2020-11-25T03:24:56ZengBMCArthritis Research & Therapy1478-63622019-06-012111910.1186/s13075-019-1917-8Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registryDenis Choquette0Louis Bessette1Evo Alemao2Boulos Haraoui3Roelien Postema4Jean-Pierre Raynauld5Louis Coupal6Rheumatology Research Institute of MontrealCenter for Osteoporosis and Rheumatology of Quebec (CORQ)Bristol-Myers SquibbRheumatology Research Institute of MontrealBristol-Myers SquibbRheumatology Research Institute of MontrealRheumatology Research Institute of MontrealAbstract Background Treatment persistence is an important consideration when selecting a therapy for chronic conditions such as rheumatoid arthritis (RA). We assessed the long-term persistence of abatacept or a tumor necrosis factor inhibitor (TNFi) following (1) inadequate response to a conventional synthetic disease-modifying antirheumatic drug (first-line biologic agent) and (2) inadequate response to a first biologic DMARD (second-line biologic agent). Methods Data were extracted from the Rhumadata® registry for patients with RA prescribed either abatacept or a TNFi (adalimumab, certolizumab, etanercept, golimumab, or infliximab) who met the study selection criteria. The primary outcome was persistence to abatacept and TNFi treatment, as first- or second-line biologics. Secondary outcomes included the proportion of patients discontinuing therapy, reasons for discontinuation, and predictors of discontinuation. Persistence was defined as the time from initiation to discontinuation of biologic therapy. Baseline characteristics were compared using descriptive statistics; cumulative persistence rates were estimated using Kaplan-Meier methods, compared using the log-rank test. Multivariate Cox proportional hazard models were used to compare the persistence between treatments, controlling for baseline covariates. Results Overall, 705 patients met the selection criteria for first-line biologic agent initiation (abatacept, n = 92; TNFi, n = 613) and 317 patients met the criteria for second-line biologic agent initiation (abatacept, n = 105; TNFi, n = 212). There were no clinically significant differences in baseline characteristics between the treatments with either first- or second-line biologics. Persistence was similar between the first-line biologic treatments (p = 0.7406) but significantly higher for abatacept compared with TNFi as a second-line biologic (p = 0.0001). Mean (SD) times on first-line biologic abatacept and TNFi use were 4.53 (0.41) and 5.35 (0.20) years, and 4.80 (0.45) and 2.82 (0.24) years, respectively, as second-line biologic agents. The proportion of patients discontinuing abatacept and TNFi in first-line was 51.1% vs. 59.5% (p = 0.1404), respectively. In second-line, it was 57.1% vs. 74.1% (p = 0.0031). The main reasons for stopping both treatments were inefficacy and adverse events. Conclusions Abatacept and TNFi use demonstrated similar persistence rates at 9 years as a first-line biologic agent. As a second-line biologic agent, abatacept had better persistence rates over a TNFi.http://link.springer.com/article/10.1186/s13075-019-1917-8Rheumatoid arthritisRegistryDisease-modifying antirheumatic drugs (biologic)PersistenceAbataceptTNF inhibitor |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Denis Choquette Louis Bessette Evo Alemao Boulos Haraoui Roelien Postema Jean-Pierre Raynauld Louis Coupal |
spellingShingle |
Denis Choquette Louis Bessette Evo Alemao Boulos Haraoui Roelien Postema Jean-Pierre Raynauld Louis Coupal Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry Arthritis Research & Therapy Rheumatoid arthritis Registry Disease-modifying antirheumatic drugs (biologic) Persistence Abatacept TNF inhibitor |
author_facet |
Denis Choquette Louis Bessette Evo Alemao Boulos Haraoui Roelien Postema Jean-Pierre Raynauld Louis Coupal |
author_sort |
Denis Choquette |
title |
Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry |
title_short |
Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry |
title_full |
Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry |
title_fullStr |
Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry |
title_full_unstemmed |
Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry |
title_sort |
persistence rates of abatacept and tnf inhibitors used as first or second biologic dmards in the treatment of rheumatoid arthritis: 9 years of experience from the rhumadata® clinical database and registry |
publisher |
BMC |
series |
Arthritis Research & Therapy |
issn |
1478-6362 |
publishDate |
2019-06-01 |
description |
Abstract Background Treatment persistence is an important consideration when selecting a therapy for chronic conditions such as rheumatoid arthritis (RA). We assessed the long-term persistence of abatacept or a tumor necrosis factor inhibitor (TNFi) following (1) inadequate response to a conventional synthetic disease-modifying antirheumatic drug (first-line biologic agent) and (2) inadequate response to a first biologic DMARD (second-line biologic agent). Methods Data were extracted from the Rhumadata® registry for patients with RA prescribed either abatacept or a TNFi (adalimumab, certolizumab, etanercept, golimumab, or infliximab) who met the study selection criteria. The primary outcome was persistence to abatacept and TNFi treatment, as first- or second-line biologics. Secondary outcomes included the proportion of patients discontinuing therapy, reasons for discontinuation, and predictors of discontinuation. Persistence was defined as the time from initiation to discontinuation of biologic therapy. Baseline characteristics were compared using descriptive statistics; cumulative persistence rates were estimated using Kaplan-Meier methods, compared using the log-rank test. Multivariate Cox proportional hazard models were used to compare the persistence between treatments, controlling for baseline covariates. Results Overall, 705 patients met the selection criteria for first-line biologic agent initiation (abatacept, n = 92; TNFi, n = 613) and 317 patients met the criteria for second-line biologic agent initiation (abatacept, n = 105; TNFi, n = 212). There were no clinically significant differences in baseline characteristics between the treatments with either first- or second-line biologics. Persistence was similar between the first-line biologic treatments (p = 0.7406) but significantly higher for abatacept compared with TNFi as a second-line biologic (p = 0.0001). Mean (SD) times on first-line biologic abatacept and TNFi use were 4.53 (0.41) and 5.35 (0.20) years, and 4.80 (0.45) and 2.82 (0.24) years, respectively, as second-line biologic agents. The proportion of patients discontinuing abatacept and TNFi in first-line was 51.1% vs. 59.5% (p = 0.1404), respectively. In second-line, it was 57.1% vs. 74.1% (p = 0.0031). The main reasons for stopping both treatments were inefficacy and adverse events. Conclusions Abatacept and TNFi use demonstrated similar persistence rates at 9 years as a first-line biologic agent. As a second-line biologic agent, abatacept had better persistence rates over a TNFi. |
topic |
Rheumatoid arthritis Registry Disease-modifying antirheumatic drugs (biologic) Persistence Abatacept TNF inhibitor |
url |
http://link.springer.com/article/10.1186/s13075-019-1917-8 |
work_keys_str_mv |
AT denischoquette persistenceratesofabataceptandtnfinhibitorsusedasfirstorsecondbiologicdmardsinthetreatmentofrheumatoidarthritis9yearsofexperiencefromtherhumadataclinicaldatabaseandregistry AT louisbessette persistenceratesofabataceptandtnfinhibitorsusedasfirstorsecondbiologicdmardsinthetreatmentofrheumatoidarthritis9yearsofexperiencefromtherhumadataclinicaldatabaseandregistry AT evoalemao persistenceratesofabataceptandtnfinhibitorsusedasfirstorsecondbiologicdmardsinthetreatmentofrheumatoidarthritis9yearsofexperiencefromtherhumadataclinicaldatabaseandregistry AT boulosharaoui persistenceratesofabataceptandtnfinhibitorsusedasfirstorsecondbiologicdmardsinthetreatmentofrheumatoidarthritis9yearsofexperiencefromtherhumadataclinicaldatabaseandregistry AT roelienpostema persistenceratesofabataceptandtnfinhibitorsusedasfirstorsecondbiologicdmardsinthetreatmentofrheumatoidarthritis9yearsofexperiencefromtherhumadataclinicaldatabaseandregistry AT jeanpierreraynauld persistenceratesofabataceptandtnfinhibitorsusedasfirstorsecondbiologicdmardsinthetreatmentofrheumatoidarthritis9yearsofexperiencefromtherhumadataclinicaldatabaseandregistry AT louiscoupal persistenceratesofabataceptandtnfinhibitorsusedasfirstorsecondbiologicdmardsinthetreatmentofrheumatoidarthritis9yearsofexperiencefromtherhumadataclinicaldatabaseandregistry |
_version_ |
1724598952065499136 |